Synthesis, characterization, and imaging performance of a new class of macrocyclic hepatobiliary MR contrast agents

Investigative Radiology

Volumn 35, Issue 1, 2000, Pages 8-24

  Marinelli, Edmund R ^a   Neubeck, Richard ^b   Song, Bo ^a   Wagler, Thomas ^c   Ranganathan, Ramachandran S ^a   Sukumaran, Kozikhott ^a   Wedeking, Paul W ^a   Nunn, Adrian ^a   Runge, Val M ^d   Tweedle, Michael F ^a  

^a Bracco Research USA   (United States)

^b PHARMACOPEIA INC   (United States)

^c FMC CORPORATION   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Contrast enhancement; Contrast media, liver, MR; Gadolinium; Liver neoplasms

Indexed keywords

GADOLINIUM 2,5 TERT BUTYLPHENYLAMIDO 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7 TRIACETIC ACID; GADOLINIUM CHELATE; GADOTERIDOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG TOLERANCE; HEPATOBILIARY SYSTEM; LIVER TUMOR; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

EID: 12944259147     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-200001000-00002     Document Type: Article

References (66)

1. Tweedle MF. Relaxation agents in NMR imaging. In: Bunzli JCG, Choppin GR, eds. Lanthanide probes in life, chemical and earth science. Amsterdam: Elsevier, 1989;127-179.
2. Kumar K. Macrocyclic polyaminocarboxylate complexes of Gd(III) as magnetic resonance imaging contrast agents. J Alloys Compd 1997; 249:163-172.
3. Hamm B, Wolf K-J, Felix R. Conventional and rapid MR imaging of the liver with Gd-DTPA. Radiology 1987;164:313-320.
4. Weinmann HJ, Brasch RC, Press WR, Wesby GE. Characteristics of gadolinium-DTPA complex: A potential NMR contrast agent. AJR 1984;142:619-624.
5. Ito K, Mitchell DG, Honjo K, et al. Biphasic contrast-enhanced multisection dynamic MR imaging of the liver: Potential pitfalls. Radiographics 1997;17:693-705.
6. Hamm B, Mahfouz AE, Taupitz M, et al. Liver metastases: Improved detection with dynamic gadolinium-enhanced MR imaging? Radiology 1997;202:677-682.
7. Runge VM. Evaluation of standard and high-dose contrast-enhanced breath-hold liver magnetic resonance for visualization of metastatic disease in an animal model. Invest Radiol 1998;33:263-267.
8. Runge VM, Kirsch JE, Wells JW, et al. Enhanced liver MR: Contrast agents and imaging strategy. Crit Rev Diagn Imaging 1993;34:1-30.
9. Petersein J, Saini S, Weissleder R. Liver II: Iron oxide-based recticuloendothelial contrast agents for MR imaging. Magn Reson Imaging Clin North Am 1996;4:61-72.
10. Clement O, Siauve N, Cuenod C-A, Frija G. Liver imaging with ferumoxides (Feridex): Fundamentals, controversies, and practical aspects. Top Magn Reson Imag 1998;9:167-182.
11. Clement O, Siauve N, Lewin M, et al. Contrast agents in magnetic resonance imaging of the liver: Present and future. Biomed Pharmacother 1998;52:51-58.
12. Runge VM. A comparison of two MR hepatobiliary gadolinium chelates: Gd-BOPTA and Gd-EOB-DTPA. J Comput Assist Tomogr 1998;22:643-650.
13. Kirchin MA, Pirovano GP, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA): An overview. Invest Radiol 1998;33:798-809.
14. Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, et al. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 1992;183:59-64.
15. Coffin CM, Diche T, Mahfouz A, et al. Benign and malignant hepatocellular tumors: Evaluation of tumoral enhancement after mangafodipir trisodium injection on MR imaging. Eur Radiol 1999;9: 444-449.
16. Muller M, Jansen PL. Molecular aspects of hepatobiliary transport. Am J Physiol 1997;272(6 Pt 1):G1285-G1303.
17. Smith RL. The excretory function of bile. London: Chapman and Hall, 1973.
18. Stremmel W, Diede HE. Cellular uptake of conjugated bilirubin and sulfobromophthalein (BSP) by the human hepatoma cell line Hep G2 is mediated by a membrane BSP/bilirubin binding protein. J Hepatol 1990;10:99-104.
19. Tirribelli C, Lunazzi GC, Sottocasa GL. Biology of bilitranslocase. In: Tavoloni N, Berk PD, eds. Hepatic transport and bile secretion: Physiology and pathophysiology. New York: Raven, 1993;235-244.
20. Wolkoff AW, Sosiak A, Greenblatt HC, et al. Immunological studies of an organic anion-binding protein isolated from rat liver cell plasma membrane. J Clin Invest 1985;76:454-459.
21. Wolkoff AW. Hepatocyte organic anion binding protein. In: Tavolini N, Berk PD, eds. Hepatic transport and bile secretion: Physiology and pathophysiology. New York: Raven, 1993;269-280.
22. Stremmel W, Tiribelli C, Vyska K. The multiplicity of sinusoidal membrane carrier systems of organic anions. In: Tavolini N, Berk PD, eds. Hepatic transport and bile secretion: Physiology and pathophysiology. New York: Raven, 1993;225-233.
23. Fuchs WA. Physiology of biliary excretion of roentgenographic contrast media. Radiologe 1977:17:64-69.
24. Berk RN, Loeb PM. Pharmacology and physiology of the biliary radiographic contrast materials. Semin Roentgenol 1976;11:147-156.
25. Nunn AD, Loberg MD, Conley RA. A structure-distribution-relationship approach leading to the development of technetium-99m-labeled mebrofenin: An improved cholescintigraphic agent. J Nucl Med 1983;24:423-430.
26. Tirone P, Rosati G. Radiopaque contrast media. XXXVII-Iopronic acid, a new contrast medium for oral cholecystography: Pharmacologic investigation. Farmaco [Prat] 1976;31:397-412.
27. Rosenberg FJ, Ackerman JH, Nickel AR. Iosulamide: A new intravenous cholangiocholecystographic medium. Invest Radiol 1980;15(6 Suppl):S142-147.
28. Langecker H, Harwart A, Junkmann K. 3,5-Diacetamido-2,4,6-triiodo-benzoic acid as an x-ray contrast medium. Arch Exp Pathol Pharmakol 1954;222:584-590.
29. Ranganathan RS, Marinelli ER, Pillai KMR, Tweedle MF. Aromatic amide compounds and metal chelates thereof. U.S. Patent 5,573,752, Nov. 12, 1996.
30. Hagan JJ, Taylor SC, Tweedle MF. Fluorescence detection of gadolinium chelates separated by reversed-phase high-performance liquid chromatography. Anal Chem 1988;60:514-516.
31. Kumar K, Sukumaran S, Chang CA, et al. True tracer radiolabeling of gadolinium complex of 10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (HP-DO3A). J Lab Cpds Radiopharm 1993;33:473-482.
32. Hansch C, Leo A. Substituent constants for correlation analysis in chemistry and biology. New York: Wiley Interscience, 1979;37.
33. Purcell W, Bass G, Clayton J. Strategy of drug design. New York: Wiley Interscience, 1973.
34. Kumar K, Sukumaran K, Taylor S, et al. Partition coefficients (log P) and HPLC capacity factors (k) of some Gd(III) complexes of linear and macrocyclic polyamino carboxylates. J Liq Chromatogr 1994; 17:3735-3746.
35. Kumar K, Chang C, Francesconi LC, et al. Synthesis, stability, and structure of gadolinium(III) and yttrium(III) macrocyclic poly-(amino carboxylates). Inorg Chem 1994;33:3567-3575.
36. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council. Guide for the care and use of laboratory animals. Washington DC: National Academy Press, 1966.
37. Offert ED. Considerations for defining an acceptable endpoint in toxicological experiments. Lab Anim 1966;30:38-43.
38. n in mice. Nucl Med Biol 1988;15:395-402.
39. Hayes CE, Edelstein WA, Schenck JF, et al. An efficient, highly homogeneous RF coil for whole-body NMR imaging at 1.5 T. J Magn Reson 1985;63:622-628.
40. Runge VM, Wells JW, Williams NM. Evaluation of gadolinium 2,5-BPA-DO3A, a new macrocyclic hepatobiliary chelate, in normal liver and metastatic disease on high field magnetic resonance imaging. Invest Radiol 1996;31:11-16.
41. Lochamy JC, The minimum-detectable-activity concept. NBS Publication No. SP456, Washington DC, 1976.
42. Altman PL. Blood and other body fluids. New York: Macmillan, 1954.
43. Barluenga J, Villamana J, Yus M. Aminomercuration-demurcuration of α,β-unsaturated esters; synthesis of N-aryl-β-aminocarboxylic esters. Synthesis 1981;375-376.
44. Rumpf P. Preparation of aminoalkylsulfonic acids with a view to a comparative physiochemical study. Bull Soc Chim Fr 1938;5:871-888.
45. Padwa A, Chen YY, Dent W, Nimmesgern H. Synthetic application of cyanoaminosilanes as azomethine ylide equivalents. J Org Chem 1985;50:4006-4014.
46. Sawicki E. A convenient synthesis of 2-β-hydroxyethylaminofluorene. J Am Chem Soc 1953;75:4596.
47. Rudesill JT, Severson RF, Pomonis, JG. The synthesis of N-arylaziridines. J Org Chem 1971;36:3071-3076.
48. Prasad JS, Okuniewicz FJ, Delaney EJ, Dischino DD. Synthesis of gadolinium (±)-10-(1-hydroxypropan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7- triyltriacetate via tribenzyl 1,4,7,10-tetraazacyclododecane-1,4,7-tricarboxylate. J Chem Soc Perkin Trans 1 1991; 12:3329-3332.
49. Berg A, Almen T, Thomassen T, et al. Preparation of chelates of aminopolycarboxylates as therapeutic and diagnostic agents. European Patent Application, 42 pp, EP 299795 AI 890118, 1989.
50. Cavagna F, Tirone P, Felder E, DeHaen C. Hepatobiliary contrast agents for MRI. In: Ferrucci JT, Stark DD, eds. Liver imaging: Current trends and new techniques. Boston: Andover Medical Publishers, 1990;384-393.
51. Vittadini G, Felder E, Tirone P, Lorusso V. B-19036, a potential new hepatobiliary contrast agent for MR proton imaging. Invest Radiol 1988;23(Suppl 1):S246-248.
52. Snedecor GW, Cochran WG. Statistical methods. 7th ed. Ames, Iowa: Iowa State University Press, 1980;83-88.
53. Leo A, Hansch C, Elkins D. Partition coefficients and their uses. Chem Rev 1971;71:535.
54. Leo A, Hansch C, Elkins D. Partition coefficients and their uses. Chem Rev 1971;71:544-545.
55. Molter J, Kloss G. Preparation of various IDA derivatives. J Lab Cpds Radiopharm 1981;18:56-58.
56. Loberg M, Nunn AD, Porter DW. Development of hepatobiliary imaging agents. In: Freeman LM, Freeman HS, eds. Nuclear medicine annual. New York: Raven Press, 1981;1-33.
57. 99mTc-labeled hepatobiliary agents. J Nucl Med 1977;18:455-461.
58. 99mTc-labelled N-substituted carbamoyl iminodiacetates: Relations between structure and biodistribution. Int J Nucl Med Biol 1980;7:1-7.
59. 99mTc-labelled acetanilido iminodiacetates. Eur J Nucl Med 1981;6:241-244.
60. Jansholt A-L, Schiebe PO, Vera DR, et al. Use of quantitative structure-activity analysis in radiopharmaceutical design. In: Reynaud C, ed. Proceedings of Third World Congress of Nuclear Medicine and Biology. Vol. 1. Paris: Pergamon Press, 1982;261-264.
61. Chen G, Ensor CR, Russel D, Bohner B. The pharmacology of 1-(1-phenylcyclohexyI)piperidine•HCl. J Pharmacol Exp Ther 1959;127:241-250.
62. McAfee JG, Subramanian G. Experimental models and evaluation of animal data for renal radiodiagnostic agents. In: Lambrecht RM, Eckelman WC, eds. Animal models in radiotracer design. New York: Springer-Verlag, 1983:211.
63. Lang JH, Lasser EC. Nonspecific inhibition of enzymes by organic contrast media. J Med Chem 1971;14:233-236.
64. Nunn A, Wedeking P, Marinelli E, et al. Toxicity of gadolinium chelates in rodents. Acad Radiol 1996(Suppl 2):S333-S335.
65. Fritzberg AR, Bloedow DC. Animal models in the study of hepatobiliary radiotracers. In: Lambrecht RM, Eckelman WC, eds. Animal models in radiotracer design. New York: Springer-Verlag, 1983:179-209.
66. 99mTc complexes. Int J Rad Appl Instrum [B] 1989;16:191-232.